rTMS for Apathy Clinical Trial

Brief Summary

Apathy is a common, early, and disabling symptom in dementias such as Alzheimer’s disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in AD in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Eligibility Criteria

Inclusion Criteria

• Major neurocognitive disorder
• Apathy for at least 4 weeks
• Stable dose of medication (>4 weeks) that may affect cognition or behaviour
• Care partner who spends at least 10 hours a week with the subject

Exclusion Criteria

• Current major depressive episode
• Agitation, delusions, hallucination
• Medical contraindications to rTMS
• Currently taking an amphetamine product
• Central nervous system abnormalities, Tourette’s syndrome, or motor tics
• Current participation in another clinical trial